GLP-1, or {glucagon-like|glucagon like|glucagon) peptide-1, is currently gaining a prominent focus in therapeutic research, largely due to its impressive impact on treating diseases such as second type diabetes and excess body fat. New studies have shown that in addition to glucose control, GLP-1 agonists offer potential for circulatory health and